Investor Profile: Breyer Capital — Thesis, Cheque Size & How to Apply

Founders chasing Breyer Capital funding are chasing one of venture's most storied names. Founded in 2006 by Jim Breyer — the Accel partner who led the firm's legendary Facebook investment — and headquartered in Austin, Texas, Breyer Capital makes long-term, idea-driven investments in high-impact entrepreneurs, anchored by the conviction that artificial intelligence and machine learning will transform technology and investment globally.

Thesis and focus: how to get funding from Breyer Capital

The firm's creed, per its site: technology is an enabler, not a replacer. It backs founders for the long haul across artificial intelligence, healthcare and life sciences, enterprise, consumer and financial technologies. Stages are not explicitly stated by the firm. Fund size and cheque size are not publicly disclosed — treat third-party AUM estimates as unverified.

Notable portfolio

Homepage and team-page names include Meta / Facebook, Spotify, Etsy, Grammarly, Epic Games, Circle, Shield AI, Lyra Health, Sandbox AQ, Legendary and Marvel — plus partner-led investments including Zepto (India, via Daniel Breyer), Headspace, Stash, TapTap Send, Wasoko and Jona Health.

Partners

Beyond founder Jim Breyer, the team page lists Morgan Cheatham (Partner and Head of Healthcare and Life Sciences), Daniel Breyer (Partner), Ted Breyer (Partner, leads fintech investing), Samuel J. Palmisano (Venture Advisor; former IBM chairman and CEO), Bret L. Bostwick, MD (Venture Advisor) and Leo Grady (CEO in Residence; founder/CEO of Jona Health).

How to apply for funding

There is no pitch portal and no public submission process on the firm's site; founders reach the team via the website's contact routes. Realistically, Breyer Capital is a relationship-driven firm — a warm introduction from a portfolio founder or co-investor is the credible path in, and AI-native ambition is table stakes.

The firm's AI conviction runs through its recent team-building: in April 2025 it named Morgan Cheatham as Partner and Head of Healthcare and Life Sciences, and its site frames technology as "an enabler not a replacer" — a philosophy that shapes its healthcare and enterprise bets. With venture advisors including former IBM chairman and CEO Samuel J. Palmisano and a CEO-in-residence programme, the firm offers founders access to operators who have run some of the world's largest technology companies.